Peyronie's Disease Society - Forum
March 14, 2010, 04:38:49 PM *
Welcome, Guest. Please login or register.

Login with username, password and session length
News: Visit our Website at http://www.PeyroniesSociety.org
 
   Home   Help Search Calendar Login Register  
Visit the Peyronies Disease Society's website
Pages: [1]   Go Down
  Print  
Author Topic: DHEA  (Read 268 times)
0 Members and 1 Guest are viewing this topic.
slowandsteady
Major Contributor
****
Offline Offline

Gender: Male
Posts: 275


« Reply #1 on: October 25, 2009, 03:28:39 PM »

In a mouse model, "[a]dministration of exogenous DHEA ameliorates the severity of acute and chronic [antigen-induced arthritis], presumably by suppressing cell-mediated immunity against mBSA (the inducing antigen) and formation of autoantibodies. However, because of the fundamentally different DHEA physiology in rodents, the role of such a replacement therapy in human RA deserves further elucidation" (PMID 15105968). The protection against of antigen-induced arthritis is interesting in Peyronies Disease because of the autoimmune component it seem to have.
Logged
slowandsteady
Major Contributor
****
Offline Offline

Gender: Male
Posts: 275


« on: October 25, 2009, 03:21:25 PM »

More information on DHEA. In the article Marked attenuation of production of collagen type I from cardiac fibroblasts by dehydroepiandrosterone:

Quote
Dehydroepiandrosterone (DHEA) is a type of adrenal steroid. The concentrations of DHEA and its sulfate (DHEA-S) in serum reach a peak between the ages of 25 and 30 yr and thereafter decline steadily. It was reported that DHEA-S concentration in humans is inversely related to death from cardiovascular diseases. In this study, we examined the effects of DHEA on regulation of collagen mRNA and collagen synthesis in cultured cardiac fibroblasts. Treatment with DHEA (10–6 M) resulted in a significant decrease in procollagen type I mRNA expression compared with controls. This was accompanied by a significant decrease in procollagen type I protein accumulation in the medium and also a significant decrease in procollagen type I protein synthesis in the cellular matrix. Furthermore, to confirm in vitro results, we administered DHEA to Sprague-Dawley rats, which were treated with angiotensin II for 8 wk to induce cardiac damage. Procollagen type I mRNA expression was significantly decreased and cardiac fibrosis significantly inhibited in DHEA-treated rat hearts without lowering the systolic blood pressure. These results strongly indicate that DHEA can directly attenuate collagen type I synthesis at the transcriptional level in vivo and in vitro in cardiac fibroblasts.

Anecdotally, I do seem to get relief from 300 mg of 7-keto-DHEA in the mornings, and it seems to be repeatable too. I might play around with the dose a bit and get DHEA-S levels retested.
Logged
Pages: [1]   Go Up
  Print  
 
Jump to:  

Visit the Peyronies Disease Society's website
Powered by MySQL Powered by PHP Powered by SMF 1.1.10 | SMF © 2006-2009, Simple Machines LLC Valid XHTML 1.0! Valid CSS!


Google visited last this page February 07, 2010, 08:00:18 AM